Comparison of transcriptional profiles of interferons, CXCL10 and RIG-1 in influenza infected A549 cells stimulated wiThexogenous interferons

Acta Virologica

Volumn 61, Issue 2, 2017, Pages 183-190

  Lachova V ^a   Skorvanova L ^a   Svetlikova D ^a   Turianova L ^a   Kostrabova A ^b   Betakova T ^a,b  

^a INSTITUTE OF VIROLOGY   (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

Author keywords

CXCL10; Influenza virus; Interferon; mRNA; RIG 1

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BETA1A INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON LAMBDA3; INTERFERON OMEGA; INTERLEUKIN 28A; INTERLEUKIN 29; MESSENGER RNA; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; STAT2 PROTEIN; UNCLASSIFIED DRUG; RARRES3 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; TRANSCRIPTOME;

A-549 CELL LINE; ARTICLE; COMPARATIVE STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC TRANSCRIPTION; INFLUENZA A VIRUS (H7N7); NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VIRUS CELL INTERACTION; ADENOCARCINOMA; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CHEMOKINE CXCL10; GENE EXPRESSION REGULATION; HUMANS; INTERFERONS; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 85020433639     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2017_02_07     Document Type: Article

References (49)

1. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR (2008): An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J. Immunol. 180, 2474-2485. https://doi. org/10.4049/jimmunol.180.4.2474
2. Au WC, Yeow WS, Pitha PM (2001): Analysis of functional domains of interferon regulatory factor 7 and its association with IRF-3. Virology 280: 273-282. https://doi.org/10.1006/ viro.2000.0782
3. Biron CA (1999): Initial and innate responses to viral infectionspattern setting in immunity or disease. Curr. Opin. Microbiol. 2, 374-381. https://doi.org/10.1016/S1369-5274(99)80066-6
4. Blazek K, Eames HL, Weiss M, Byrne AJ, Perocheau D, Pease JE, Doyle S, McCann F, Williams RO, Udalova IA (2015): IFN-γ resolves infl ammation via suppression of neutrophil infiltration and IL-1β production. J. Exp. Med. 212, 845-853. https://doi.org/10.1084/jem.20140995
5. Bolen CR, Ding S, Robek MD, Kleinstein SH (2014): Dynamic expression profiling of type I and type III interferonstimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 59, 1262-1272. https://doi. org/10.1002/hep.26657
6. Brownell J, Wagoner J, Lovelace ES, Thirstrup D, Mohar I, Smith W, Giugliano S, Li K, Crispe IN, Rosen HR, Polyak SJ (2013): Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes. J. Hepatol. 59, 701-708. https://doi.org/10.1016/j.jhep.2013.06.001
7. Cleary CM, Donnelly RJ, Soh J, Mariano TM, Pestka S (1994): Knockout and reconstitution of a functional human type I interferon receptor complex. J. Biol. Chem. 269, 18747-18749
8. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, Cella M, Lande R, Uzé G (2004): Viral infection and Toll-like receptor agonists induce a diff erential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34, 796-805. https://doi.org/10.1002/eji.200324610
9. Cohen TS, Parker D (2016): Microbial pathogenesis and type III interferons. Cytokine Growth Factor Rev. 29, 45-51. https:// doi.org/10.1016/j.cytogfr.2016.02.005
10. Cohen TS, Prince AS (2013): Bacterial pathogens activate a common infl ammatory pathway through IFNγ regulation of PDCD4. PLoS Pathog. 9, e1003682. https://doi. org/10.1371/journal.ppat.1003682
11. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM (2006): Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44, 896-906. https:// doi.org/10.1002/hep.21312
12. Durbin RK, Kotenko SV, Durbin JE (2013): Interferon induction and function at the mucosal surface. Immunol. Rev. 255, 25-39. https://doi.org/10.1111/imr.12101
13. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC (2004): Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling J. Biol. Chem. 279, 32269-32274. https://doi.org/10.1074/jbc.M404789200
14. Gao W, Sun W, Qu B, Cardona CJ, Powell K, Wegner M, Shi Y, Xing Z (2012): Distinct regulation of host responses by ERK and JNK MAP kinases in swine macrophages infected with pandemic (H1N1) 2009 infl uenza virus. PLoS One 7, e30328. https://doi.org/10.1371/journal.pone.0030328
15. Hamming OJ, Terczynska-Dyla E, Vieyres G, Dijkman R, Jørgensen SE, Akhtar H, Siupka P, Pietschmann T, Thiel V, Hartmann R (2013): Interferon lambda 4 signals via the IFNγ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 32, 3055-3065. https://doi. org/10.1038/emboj.2013.232
16. Helbig KJ, Ruszkiewicz A, Lanford RE, Berzsenyi MD, Harley HA, McColl SR, Beard MR (2009): Diff erential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J. Virol. 83, 836-846. https://doi.org/10.1128/JVI.01388-08
17. Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, Goto K, Brisac C, Chusri P, Fusco DN, Chevaliez S, Luther J, Kumthip K, Urban TJ, Peng LF, Lauer GM, Chung RT (2014): Kinetic diff erences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 59, 1250-1261. https://doi.org/10.1002/hep.26653
18. Jewell NA, Cline T, Mertz SE, Smirnov SV, Fla-o E, Schindler C, Grieves JL, Durbin RK, Kotenko SV, Durbin JE (2010): Lambda interferon is the predominant interferon induced by infl uenza A virus infection in vivo. J. Virol. 84, 11515-11522. https://doi.org/10.1128/JVI.01703-09
19. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. (2003): IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69-77. https://doi.org/10.1038/ni875
20. Kotenko SV, Langer JA (2004): Full house: 12 receptors for 27 cytokines. Int. Immunopharmacol. 4, 593-608. https:// doi.org/10.1016/j.intimp.2004.01.003
21. Liu Y, Chen L, Zou Z, Zhu B, Hu Z, Zeng P, Wu L, Xiong J (2016): Hepatitis C virus infection induces elevation of CXCL10 in human brain microvascular endothelial cells. J. Med. Virol. 88, 1596-603. https://doi.org/10.1002/jmv.24504
22. Lopušná K, Režuchová I, Betáková T, Škovranová L, Tomašková J, Lukáciková L, Kabát P (2013): Interferons lambda, new cytokines with antiviral activity. Acta Virol. 57, 171-179. https://doi.org/10.4149/av_2013_02_171
23. Ludwig S, Wang X, Ehrhardt C, Zheng H, Donelan N, Planz O, Pleschka S, García-Sastre A, Heins G, Wolff T (2002): The infl uenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors. J. Virol. 76, 11166-11171. https://doi.org/10.1128/ JVI.76.21.11166-11171.2002
24. Lukacikova L, Oveckova I, Betakova T, Laposova K, Polcicova K, Pastorekova S, Pastorek J, Tomaskova J (2015): Antiviral effect of interferon lambda against lymphocytic choriomeningitis virus. J. Interferon Cytokine Res. 35, 540-553. https://doi.org/10.1089/jir.2014.0083
25. Luster AD, Ravetch JV (1987): Genomic characterization of a gamma-interferon-inducible gene (IP-10) and identifi cation of an interferon-inducible hypersensitive site. Mol. Cell. Biol. 7, 3723-3731. https://doi.org/10.1128/ MCB.7.10.3723
26. Mahlakõiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P (2015): Leukocyte-derived IFN-α/β and epithelial IFN-γ constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 11, e1004782. https://doi.org/10.1371/journal.ppat.1004782
27. Mibayashi M, Martínez-Sobrido L, Loo YM, Cárdenas WB, Gale M Jr, García-Sastre A (2007): Inhibition of retinoic acidinducible gene I-mediated induction of beta interferon by the NS1 protein of infl uenza A virus. J. Virol. 81, 514-524. https://doi.org/10.1128/JVI.01265-06
28. Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, Bartenschlager R, Ramadori G (2004): Interferon type I gene expression in chronic hepatitis C. Lab. Invest. 84, 1148-1159. https://doi.org/10.1038/labinvest.3700135
29. Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, Boulant S, Gehrke L, Cossart P, Kagan JC (2014): Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat. Immunol. 15, 717-726. https://doi.org/10.1038/ni.2915
30. Padovan E, Spagnoli GC, Ferrantini M, Heberer M (2002): IFNalpha2a inducesIP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J. Leukoc. Biol. 71, 669-676
31. Pestka S, Langer JA, Zoon KC, Samuel CE (1987): Interferons and their actions. Annu. Rev. Biochem. 56, 727-777. https:// doi.org/10.1146/annurev.bi.56.070187.003455
32. Pestka S, Krause CD, Walter MR (2004): Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8-32. https://doi.org/10.1111/j.0105-2896.2004.00204.x
33. Pichlmair A, Schulz O, Tan CP, Näslund TI, Liljeström P, Weber F, Reise Sousa C (2006): RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 314, 997-1001 https://doi.org/10.1126/science.1132998
34. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR (2013): A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164-171. https://doi.org/10.1038/ng.2521
35. Runkel L, Pfeffer L, Lewerenz M, Monneron D, Yang CH, Murti A, Pellegrini S, Goelz S, Uzé G, Mogensen K (1998): Diff erences in activity between alpha and beta type I interferons explored by mutational analysis. J. Biol. Chem. 273, 8003-8008. https://doi.org/10.1074/jbc.273.14.8003
36. Sheppard P, Kindsvogel W, Xu W et al. (2003): IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63-68. https://doi.org/10.1038/ni873
37. Škorvanová L, Švancarová P, Svetlíková D, Betáková T (2015): Protective efficacy of IFN-γ and IFN-γs against infl uenza viruses in induced A549 cells. Acta Virol. 59, 413-417. https://doi.org/10.4149/av_2015_04_413
38. Sommereyns C, Paul S, Staeheli P, Michiels T (2008): IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4, e1000017. https://doi.org/10.1371/journal. ppat.1000017
39. Svancarova P, Svetlikova D, Betakova T (2015a): Induction of interferon lambda in infl uenza A virus infected cells treated with shRNAs against M1 transcript. Acta Virol. 59, 148-155. https://doi.org/10.4149/av_2015_02_148
40. Svancarova P, Svetlikova D, Betakova T (2015b): Synergic and antagonistic effect of small hairpin RNAs targeting the NS gene of the infl uenza A virus in cells and mice. Virus Res. 195, 100-111. https://doi.org/10.1016/j. virusres.2014.08.004
41. Svetlikova D, Kabat P, Ohradanova A, Pastorek J, Betakova T (2010): Infl uenza A virus replication is inhibited in IFN-γ2 and IFN-γ3 transfected or stimulated cells. Antiviral Res. 88, 329-233. https://doi.org/10.1016/j.antiviral.2010.10.005
42. Thanos D, Maniatis T (1995): Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 83, 1091-100. https://doi.org/10.1016/0092-8674(95)90136-1
43. Varga ZT, Ramos I, Hai R, Schmolke M, García-Sastre A, Fernandez-Sesma A, Palese P (2011): The infl uenza virus protein PB1-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein. PLoS Pathog 7, e1002067. https://doi.org/10.1371/journal.ppat.1002067
44. Villarroel VA, Okiyama N, Tsuji G, Linton JT, Katz SI (2014): CXCR3-mediated skin homing of autoreactive CD8 T cells is a key determinant in murine graft-versus-host disease. J. Invest. Dermatol. 134, 1552-1560. https://doi. org/10.1038/jid.2014.2
45. Uzé G, Lutfalla G, Gresser I (1990): Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell 60, 225-234. https://doi. org/10.1016/0092-8674(90)90738-Z
46. Uzé G, Monneron D (2007): IL-28 and IL-29: newcomers to the interferon family. Biochimie 89, 729-734. https://doi. org/10.1016/j.biochi.2007.01.008
47. Xu C, Song X, Fu L, Dong D, Wu S, Li G, Yi S, Yu T, Yu R, Hou L, Chen W (2011): Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009 A (H1N1) infl uenza virus. Viral Immunol. 24, 369-374. https://doi. org/10.1089/vim.2011.0003
48. Zhang S, Sun Y, Chen H, DaY Y, Zhang Y, Yu S, Qiu X, Tan L, Song C, Ding Ch (2014). Activation of the PKR/eIF2a signaling cascade inhibits replication of Newcastle disease virus, Virology J. 11, 62. https://doi.org/10.1186/1743-422X-11-62
49. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R (2007): Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81, 7749-7758. https://doi.org/10.1128/JVI.02438-06